Human Prothrombin Complex (PCC) (Beriplex P/N) in the emergency reversal of anticoagulation BCSLS Congress 2012 Kamloops, BC
|
|
- Thomas Wood
- 6 years ago
- Views:
Transcription
1 Human Prothrombin Complex (PCC) (Beriplex P/N) in the emergency reversal of anticoagulation BCSLS Congress 2012 Kamloops, BC Ayman Kafal Medical Affairs, Leader CSL Behring Canada 1
2 Prothrombin Complex Concentrate in anticoagulant reversal
3 Contents Anticoagulant reversal Epidemiology Mode of action Guidelines Prothrombin complex concentrates Beriplex P/N History and differentiation Indications and clinical use Clinical studies in anticoagulant reversal Challenges of the new Oral Anticoagulants What do we know? 3
4 Epidemiology
5 Epidemiology of oral anticoagulation therapy France Netherlands USA Canada Population 60 million 16.3 million 280 million 34 million Oral anticoagulation 600,000 (1.0%) 325,072 (2.0%) 2,500,000 (0.9%) 306,000 (0.9%) Leading drug Phenindione Acenocoumarol Warfarin Warfarin 5 Pengo et al. J Thromb Thrombolysis 2006; 21: 73 7
6 Primary indications for warfarin in clinical practice in the USA Primary indication Percentage of use Atrial fibrillation 39% DVT or pulmonary embolism 27% Valve replacement 13% Cardiomyopathy 10% Stroke 6% Other venous thrombosis 1% Left ventricular thrombus 1% Peripheral vascular disease 1% Other arterial thrombosis 1% N=1020 patients taking warfarin; DVT, deep vein thrombosis 6 Wittkowsky and Devine. Pharmacotherapy 2004; 24:
7 Bleeding risk in oral anticoagulant therapy Major haemorrhage episodes per 100 patient-years (population cohort studies) % (clinical trials) Minor haemorrhage 2 24 episodes per 100 patient-years US: 26, ,000 major bleeds/year estimated Intracranial bleeding associated with oral anticoagulation Approximately 13,000 cases per year in US ~70% intracerebral bleeds ~30% subdural haematomas Mortality from intracranial bleeds ~60% Progression of bleeding in ~50% of patients within 24 hours 7 Flaherty et al. Neurology 2007; 68:116 21; Libby and Garcia. Arch Intern Med 2002; 162: ; McMahan et al. J Gen Intern Med 1998; 13: ; Schulman. N Engl J Med 2003; 349:
8 Mode of action of anticoagulant reversal
9 Mode of action of vitamin K antagonists Vitamin K Reductase Targets Factors II, VII, IX, X Proteins C and S Reductase Vitamin K H 2 Glutamic acid Vitamin K oxide -Carboxyglutamic acid Oral anticoagulation agents (warfarin, phenprocoumon, fluindione and acenocoumarol) block both reduction steps 9 Adapted from Hirsh J, et al. Chest 1995; 108:
10 10 Options available for reversal of oral anticoagulation Coagulation factor concentrates (e.g. Beriplex P/N) Contain all clotting factors required in a concentrated form Fast application possible Low volume (20ml) Predictable and measurable effect A demonstrated rapid decrease in INR to 1.3 within 30 min after administration of Beriplex P/N* *PM Beriplex P/N (human prothrombin complex),nov 5, Vitamin K Available orally or intravenous Readily available and inexpensive Response slow and unpredictable Not appropriate for emergencies Human plasma (e.g. FFP, 24-hour plasma) Contains factors that are required and some that are not required Risk of fluid overload and viral transmission Longer time required to thaw and transfuse the product Duration of infusion requires patient monitoring May fail to completely reverse anticoagulation FFP, Fresh Frozen Plasma; FVIIa, activated Factor VII Source: The Pharmacology and Management of Vitamin K Antagonists, CHEST, September 2004
11 Prothrombin complex concentrates in anticoagulant reversal
12 Emergency reversal of oral anticoagulation Human plasma PCC Volume High Low Availability Widespread Widespread Speed of administration Slow Rapid Preparation time Slow Rapid Virus inactivation procedure Pooled SD plasma: yes single donor plasma: no SD plasma: yes single donor plasma: no Yes Yes Blood group Group specific Not group specific 12 Balanced factor content Thrombogenicity SD, solvent-detergent inactivated Every factor present, high inter-individual variation SD plasma: yes Methylene blue: yes Concentrated factors and thromboinhibitors Variable between PCCs PCC, prothrombin complex concentrate Hanley. J Clin Pathol 2004; 57: ; Stanworth, et al. Br J Haematol 2004; 126: ; Makris et al. Br J Haematol 2001; 114: ; Kohler. Thromb Res 1999; 95: S13 7
13 Median clotting factor values (IU/dL) Median clotting factor values (IU/dL) Emergency reversal of oral anticoagulation: fresh frozen plasma vs PCCs Pre-treatment Post-treatment FFP (800 ml) PCC (25 50 IU FIX/kg) II VII IX X 0 II VII IX X Factor Factor patients were enrolled in the study. The objectify was to compare the efficacy of infusion of fresh frozen plasma (FFP) and clotting factor concentrates on correction of the coagulation FFP, fresh frozen plasma; PCC, prothrombin complex concentrate Makris et al. Thromb Haemost 1997; 77:
14 What is the ideal prothrombin complex concentrate? Rapid response time Balance of coagulation factors and thromboinhibitors Normalisation of INR Ideal PCC Virus inactivated 14 Fast coagulation correction Easy and fast to administer INR, International Normalised Ratio; PCC, prothrombin complex concentrate Spahn DR, Cerny V, Coats TJ, et al. Management of bleeding following major trauma: a European guideline. Crit Care 2007; 11: R17 doi: /cc5686 Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res 1999; 95: S13 17
15 PCC : Coagulation factors One 20mL vial contains: Component octaplex Beriplex in vivo T1/2 Factor II IU IU ~60h Factor VII IU IU ~4h Factor IX IU IU ~17h Factor X IU IU ~31h Protein C IU IU ~47h Protein S IU IU ~49h Heparin IU 8-40 IU Sodium citrate mm 3 mm Samama, CM. Prothrombin Complex Concentrates: A Brief Review. Euro J Anaes 2008; 25: Beriplex Product Monograph, November
16 Beriplex P/N(Human prothrombin complex)- history and differentiation
17 Product features of Beriplex P/N Beriplex P/N (Human Prothrombin Complex) is a balanced PCC, which contains all the components necessary to rapidly restore haemostasis in a bleeding emergency caused by vitamin K antagonists. Beriplex P/N contains all essential coagulation factors: Factor II, Factor VII, Factor IX and Factor X Beriplex P/N contains the thromboinhibitors: Protein C and Protein S Beriplex P/N comes in a 500 IU vial and 20 ml diluent vial Factors in Beriplex P/N are immediately bioavailable after administration Beriplex P/N is tested by PCR, nanofiltered and pasteurised with proven risk reduction for transmissable infectious agents Storage at room temperature (up to +25 C) The shelf life of Beriplex P/N is 36 months. Beriplex P/N comes with the Mix2Vial * application set Maximum infusion speed 8mL/min 17 * Mix2Vial is a registered trademark of West or one of its subsidiaries PCR, polymerase chain reaction Beriplex P/N Product Monograph, November 5, 2010
18 Indications for Beriplex P/N Beriplex P/N (Human prothrombin complex) is indicated in adults ( 18 years of age) for the treatment of bleeding and perioperative prophylaxis of bleeding in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required. No adequate study in subjects with congenital deficiency is available. Beriplex P/N can be used for the treatment of bleeding and perioperative prophylaxis of bleeding in congenital deficiency of any of the vitamin K dependent coagulation factors only if purified specific coagulation factor product is not available. 18 Beriplex P/N Product Monograph, November 5, 2010
19 Composition of Beriplex P/N Medical Ingredients Factor II Factor VII Factor IX Factor X Protein C Protein S Beriplex P/N 500 IU content per vial IU IU IU IU IU IU Beriplex P/N also contains heparin and human antithrombin III. 19 Beriplex P/N Product Monograph, November 5, 2010
20 Contraindications Known hypersensitivity to any of the components of the product Risk of thrombosis, angina pectoris, recent myocardial infarction (exception: lifethreatening haemorrhages following overdosage of oral anticoagulants, and before induction of a fibrinolytic therapy). In the case of disseminated intravascular coagulation, prothrombin complex-preparations may only be applied after termination of the consumptive state. Known history of heparin-induced thrombocytopenia 20
21 Beriplex P/N: dosing recommendations Guide for dosage: 1 IU FIX, FVII, FII, FX per kg body weight can be expected to raise FIX by 1.3%, FVII by 1.6%, FII, FX by 1.8% Required dosage: The dose will depend on the International Normalised Ratio (INR) before treatment and the targeted INR. In the following table approximate doses (ml/kg b.w.) of the reconstituted product and IU of Factor IX/kg b.w. required for normalisation of INR (e.g. 1.3) at different initial INR levels are given. Initial INR > 6.0 Approximate dose ml/kg b.w Approximate dose IU (Factor IX)/kg b.w Administered by i.v. injection Administration speed should not exceed 210 IU/min (~8 ml/min) Important for Beriplex P/N substitution: Determination of antithrombin activity in cases with suspected coagulation activation 21 i.v., intravenous Beriplex P/N Product Monograph, November 5, 2010
22 Key Features Summary Beriplex P/N Octaplex Infusion Speed 8.4ml/min Start: 1 ml/min Thereafter: 2-3 ml/min Maximum dose 5000 IU 3000 IU Double Virus Inactivation Safety Profile Nanofiltration and Pasteurisation Nanofiltration and Solvent/detergent Over 16 years UK Licence 2006 Ease and Convenience Room Temp. Storage Mix2Vial with tighter grip 3 years Mix2Vial 2 years 22
23 Beriplex P/N clinical trials in anticoagulant reversal
24 Beriplex P/N in healthy volunteers: Phase I pharmacokinetic (PK) study First study to evaluate the PK of coagulation factors and anticoagulant proteins after PCC administration 15 healthy volunteers (mean age 41 ± 13 years) Single 50 IU/kg dose of Beriplex P/N infused i.v. at a maximum rate of 210 IU/min Actual rate achieved = 7.9 ml/min Blood taken at 5, 10, 15 and 30 minutes then at frequent intervals up to 144 hours post-infusion Assess plasma levels of coagulation factors and thrombogenicity markers 24 i.v., intravenous; PCC, prothrombin complex concentrate Ostermann et al. Thromb Haemost 2007; 98: 790 7
25 Beriplex P/N Phase I PK Study: Demonstrated rapid and sustained increases in coagulation factors FX (%) FVII (%) FII (%) FIX (%) Mean PCC infusion 200IU/min; Mean PPC dose 150 ml (3750IU) Pre i.v. PCC Minutes: Post-Infusion Time Hours: Post-Infusion 25 i.v., intravenous; PCC, prothrombin complex concentrate Ostermann et al. Thromb Haemost 2007; 98: 790 7
26 Protein S (%) Protein C (%) i.v. PCC Beriplex P/N Phase I PK Study: Demonstrated rapid and sustained increases in thromboinhibitors Pre Minutes Hours Time 26 i.v., intravenous; PCC, prothrombin complex concentrate Ostermann et al. Thromb Haemost 2007; 98: 790 7
27 Beriplex P/N in anticoagulant reversal: prospective Phase III study Prospective, open, uncontrolled, multinational, Phase III study 43 patients from 25 centres in eight countries To determine the efficacy of prothrombin complex concentrates (Beriplex P/N) in the emergency reversal of oral anticoagulation when urgent surgical intervention is required in patients experiencing an acute bleed To document the safety and tolerability of Beriplex P/N Beriplex P/N dosing based on baseline INR: Baseline INR Dose of Beriplex P/N IU/kg IU/kg > IU/kg Rapid infusion: up to a maximum of 210 IU/min most patients simultaneously received i.v. vitamin K 27 INR, International Normalised Ratio; i.v., intravenous Pabinger et al. J Thromb Hemost, Volume 6, Number 4, April 2008
28 IU/mL Beriplex P/N Phase III study: coagulation factor and thromboinhibitor levels Patients receiving OAT were eligible for this prospective multinational study if their INR exceeded 2 and they required either emergency surgical or urgent invasive diagnostic intervention or INR normalization due to acute bleeding. Study endpoints included INR normalization (<1.3.) by 30 minutes after PCC infusion and haemostatic efficacy Before 30 mins 1 h 3 h 6 h 12 h 24 h 48 h Time Factor II Factor VII Factor IX Factor X Protein C Protein S 28 Pabinger et al. J Thromb Hemost, Volume 6, Number 4, April 2008
29 Mean INR ± SD Beriplex P/N Phase III study: INR response IU/kg (INR = ) 35 IU/kg (INR = ) 50 IU/kg (INR >6.0) 1 0 Pre- Inf Time after end of infusion (hours) INR, International Normalised Ratio Pabinger et al. J Thromb Hemost, Volume 6, Number 4, April 2008
30 Thank you Ayman Kafal CSL Behring Canada Medical Affairs, Leader Phone: Cell:
Appendix 3 PCC Warfarin Reversal
Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin
More informationActive date July Ratification date: Review date January 2014 Applies to: Staff managing patients on warfarin. Exclusions:
Guideline Title: Guidelines for the management of warfarin reversal [key words : Beriplex, Octaplex, PCC, vitamin K, anticoagulant, anticoagulation] Authors: Dr Sarah Allford, Consultant Haematologist
More informationMANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR
MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR 1.1 Time to lower INR Prothrombinex-VF - 15 minutes Fresh Frozen Plasma
More informationRESULT SUMMARY BE1116_3001. Acquired deficiency of prothrombin complex (reversal of oral anticoagulation)
RESULT SUMMARY Efficacy and tolerance of BERIPLEX P/N in subjects with acquired deficiency of coagulation factors II, VII, IX and X due to oral anticoagulation BE1116_3001 Investigational product: Beriplex
More informationKcentra Formulary Kit
Formulary Kit The first and only 4F-PCC for urgent warfarin reversal Important Safety Information is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation
More informationCSL Behring. Beriplex P/N 250, 500 and 1000 IU Powder and solvent for solution for injection Human prothrombin complex
CSL Behring Package leaflet: Information for the user Beriplex P/N 250, 500 and 1000 IU Powder and solvent for solution for injection Human prothrombin complex Read all of this leaflet carefully before
More informationWhen reconstituted as recommended, each vial of Prothrombinex -VF contains the ingredients listed in Table 1.
Prothrombinex -VF Malaysia NAME OF THE MEDICINE Human prothrombin complex, powder for injection. DESCRIPTION Prothrombinex -VF is a sterile freeze-dried powder containing purified human coagulation factors
More informationProthrombin Complex Concentrate- Octaplex. Octaplex
Prothrombin Complex Concentrate- Concentrated Factors Prothrombin Complex Concentrate (PCC) 3- factor (factor II, IX, X) 4-factor (factors II, VII, IX, X) Activated 4-factor (factors II, VIIa, IX, X) Coagulation
More informationBeriplex P/N 500 / Beriplex P/N 1000 Powder and solvent for solution for injection Human Prothrombin Complex
PRODUCT MONOGRAPH Beriplex P/N 500 / Beriplex P/N 1000 Powder and solvent for solution for injection Human Prothrombin Complex Factor II 380-800 IU / 760 1600 IU Factor VII 200-500 IU / 400 1000 IU Factor
More informationWhen reconstituted as recommended, each vial of Prothrombinex -VF contains the ingredients. 27 mg
Prothrombinex -VF Hong Kong NAME OF THE MEDICINE Human prothrombin complex, powder for injection. DESCRIPTION Prothrombinex -VF is a sterile freeze-dried powder containing purified human coagulation factors
More informationThe factors II, IX, X, the antithrombin III and the plasma proteins are all of human origin. The heparin sodium is of porcine origin.
New Zealand Data Sheet Prothrombinex -VF NAME OF THE MEDICINE Human prothrombin complex, powder for injection. DESCRIPTION Prothrombinex -VF is a sterile freeze-dried powder containing purified human coagulation
More informationIdelvion. (coagulation factor IX [recombinant], albumin fusion protein) New Product Slideshow
Idelvion (coagulation factor IX [recombinant], albumin fusion protein) New Product Slideshow Introduction Brand name: Idelvion Generic name: Coagulation factor IX (recombinant), albumin fusion protein
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CORE SPC FOR HUMAN PROTHROMBIN COMPLEX PRODUCTS (CPMP/BPWG/3735/02)
European Medicines Agency Human Medicines Evaluation Unit London, 21 October 2004 Corrigendum, 18 November 2004 CPMP/BPWG/3735/02 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CORE SPC FOR HUMAN
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT 500 IU powder and solvent for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION is presented as a powder and solvent
More informationTRANSPARENCY COMMITTEE OPINION. 10 March 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 March 2010 FIBROGAMMIN 62.5 U/ml, powder and solvent for injection or infusion B/1 Powder in vial + 4 ml of solvent
More informationSign up to receive ATOTW weekly -
ANTICOAGULATION & INTRACRANIAL BLEEDS - MANAGEMENT OF THE ANTICOAGULATED PATIENT PRESENTING WITH INTRACRANIAL HAEMORRHAGE ANAESTHESIA TUTORIAL OF THE WEEK 82 12 th January 2008 Rebecca Appelboam, Exeter,
More informationPOM. SUMMARY OF PRODUCT CHARACTERISTICS UK Specific
(500 IU coagulation (human factor IX prothrombin per vial, powder complex) and solvent for infusion Human Prothrombin Complex) POM SUMMARY OF PRODUCT CHARACTERISTICS UK Specific Octapharma Limited The
More informationGUIDELINES FOR MANAGEMENT OF OVER ANTICOAGULATION WITH WARFARIN
GUIDELINES FOR MANAGEMENT OF OVER ANTICOAGULATION WITH WARFARIN Version Date Purpose of Issue/Description of Change Review Date 1 29/11/05 New Policy December 2007 2 Oct 07 Review Oct 09 3 March 10 Review
More informationTitle of Guideline (must include the word Guideline (not protocol, policy, procedure etc)
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Guideline on the management of excessive coumarin anticoagulation in adults
More informationUPDATE OF NEUROCRITICAL CARE PHARMACOTHERAPY. Vera Wilson, PharmD, BCPS Emergency Services Clinical Pharmacy Specialist Johnson City Medical Center
UPDATE OF NEUROCRITICAL CARE PHARMACOTHERAPY Vera Wilson, PharmD, BCPS Emergency Services Clinical Pharmacy Specialist Johnson City Medical Center DISCLOSURE STATEMENT OF FINANCIAL INTEREST I, Vera Wilson,
More informationSummary of Product Characteristics
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT Prothromplex TOTAL 600 IU powder and solvent for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance:
More informationTrust Guideline for the Management of: Adult patients requiring anticoagulation with Warfarin (including reversal)
(including reversal) A Clinical Guideline recommended for use: In: By: For: Key words: Written by: All Clinical Areas All medical and nursing staff Adult patients requiring anticoagulation with warfarin
More informationReconstitution of Kcentra Using the Mix2Vial Transfer Set
An Instructional Guide Mix2Vial Instructional Guide has over 15 years of clinical experience as Beriplex outside the US. Reconstitution of Using the Mix2Vial Transfer Set Please see full Important Safety
More informationDeveloped for Scotland by the National Plasma Product Expert Advisory Group (NPPEAG)
Approved by NPPEAG 18 December 2018 Reviewed 18 December 2018 To be reviewed 18 December 2020 Developed for Scotland by the National Plasma Product Expert Advisory Group (NPPEAG) Protocol for the Reversal
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER Octaplex 500 IU powder and solvent for solution for infusion Human prothrombin complex Octaplex 1000 IU powder and solvent for solution for infusion Human prothrombin
More informationCoagulation, Haemostasis and interpretation of Coagulation tests
Coagulation, Haemostasis and interpretation of Coagulation tests Learning Outcomes Indicate the normal ranges for routine clotting screen and explain what each measurement means Recognise how to detect
More informationOther Components Protein C Protein S
1. NAME OF THE MEDICINAL PRODUCT Cofact 250 IU, human prothrombin complex, 250 IU factor IX per vial, powder and solvent for solution for injection. Cofact 500 IU, human prothrombin complex, 500 IU factor
More information* Sections or subsections omitted from the full prescribing information are not listed.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KCENTRA safely and effectively. See full prescribing information for KCENTRA. KCENTRA (Prothrombin
More informationPRODUCT MONOGRAPH. octaplex. Human Prothrombin Complex, freeze dried Powder and solvent for solution for injection
PRODUCT MONOGRAPH octaplex Human Prothrombin Complex, freeze dried Powder and solvent for solution for injection One vial of octaplex for solution for injection contains: octaplex 500 in 20 ml octaplex
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationGuideline for Prothrombin Complex Concentrate Utilization in Nova Scotia
Nova Scotia Provincial Blood Coordinating Program Guideline for Prothrombin Complex Concentrate Utilization in Nova Scotia Version 3.0 April 2016 PROMOTING EXCELLENCE IN TRANSFUSION MEDICINE http://novascotia.ca/dhw/nspbcp
More informationTreatment Options for Your Patients Requiring Urgent Warfarin Reversal: A Case-Based Presentation
YOU ARE INVITED TO ATTEND THIS EDUCATIONAL PROGRAM IN YOUR AREA. Treatment Options for Your Patients Requiring Urgent Warfarin Reversal: A Case-Based Presentation Educational Programs Faculty Presenter
More informationTrust Guideline for the Management of: Adult patients requiring anticoagulation with Warfarin (including reversal)
(including reversal) A Clinical Guideline recommended for use: For Use in: By: For: Division responsible for document: Key words: Name and job title of document author: Name and job title of document author
More informationUse of Prothrombin Complex Concentrates (PCC) CONTENTS
CONTENTS Page 1: Exclusion Criteria and Approved Indications for Use Page 2: Dosing / Administration / Storage Page 4: Prescribing / Monitoring / Dispensing Page 5: Cautions / Warnings / Cost Analysis
More informationReconstitution of Kcentra Using the Mix2Vial Transfer Set
An Instructional Guide years of clinical experience 20 + as Beriplex outside the US Reconstitution of Using the Mix2Vial Transfer Set Please see full Important Safety Information inside. Please see accompanying
More informationQUICK-REFERENCE SHEET
QUICK-REFERENCE SHEET Medicare Reimbursement for Hospital Inpatient Setting Under the Medicare hospital inpatient prospective payment system, each inpatient stay is assigned to a single Medicare severity
More informationManagement of the Trauma Patient. Elizabeth R Benjamin MD PhD Trauma and Surgical Critical Care Critical Care Symposium April 20, 2015
Management of the Trauma Patient Elizabeth R Benjamin MD PhD Trauma and Surgical Critical Care Critical Care Symposium April 20, 2015 Saturday Night 25 yo M s/p high speed MVC Hypotensive in the ED, altered
More informationGuidelines for the management of warfarin reversal in adults
SharePoint Location Clinical Policies and Guidelines SharePoint Index Directory General Policies and Guidelines Sub Area Haematology and Transfusion Key words (for search purposes) Warfarin, Bleeding Central
More informationANTICOAGULATION RELATED BLEEDING - GUIDELINE SUMMARY
ANTICOAGULATION RELATED BLEEDING - GUIDELINE SUMMARY Click here for the full Thrombosis Prevention Investigation and Management of Anticoagulation Guideline Click on the appropriate link below: o START
More informationOral Factor Xa Inhibitors and Clinical Laboratory Monitoring
Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring MELISSA L. WHITE ABSTRACT Oral anticoagulation therapy is currently undergoing great changes with the development and use of several new medications.
More informationADMINISTRATIVE CLINICAL Page 1 of 6
ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15
More informationTransfusion Requirements and Management in Trauma RACHEL JACK
Transfusion Requirements and Management in Trauma RACHEL JACK Overview Haemostatic resuscitation Massive Transfusion Protocol Overview of NBA research guidelines Haemostatic resuscitation Permissive hypotension
More informationPUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Cofact 250 IU and 500 IU powder and solvent for solution for injection PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Cofact contains
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationTable 1. Unit Formulation: after reconstitution with Sterile Water for Injection to 5 ml RIXUBIS 250 IU 500 IU 1000 IU 2000 IU 3000 IU
RIXUBIS rfix, Powder and Solvent for Solution for Injection NAME OF THE MEDICINE Recombinant Coagulation Factor IX (rfix), Nonacog gamma (rch) DESCRIPTION The recombinant human factor IX (rfix) is a glycoprotein
More informationAfstyla. (antihemophilic factor [recombinant] single chain) New Product Slideshow
Afstyla (antihemophilic factor [recombinant] single chain) New Product Slideshow Introduction Brand name: Afstyla Generic name: Antihemophilic Factor (recombinant), single chain Pharmacological class:
More informationBlood products and plasma substitutes
Blood products and plasma substitutes Plasma substitutes Dextran 70 and polygeline are macromolecular substances which are metabolized slowly; they may be used to expand and maintain blood volume in shock
More informationReversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017
Reversal Agents for Anticoagulants Understanding the Options Katisha Vance, MD, FACP Alabama Oncology January 28, 2017 Objectives Appropriately recommend reversal agents for Vitamin K antagonists Appropriately
More informationAppendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS
Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS Please note that newer oral anticoagulants e.g. rivaroxaban, dabigatran and apixiban should be only be considered in patients with
More informationDr Shikha Chattree Haematology Consultant Sunderland Royal infirmary
Dr Shikha Chattree Haematology Consultant Sunderland Royal infirmary Increasing use of Novel Oral Anticoagulants (NOACs) in the management of prophylaxis and management of venous thromboembolism and in
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationWARFARIN REVERSAL GUIDELINE
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
More information9310-TC-PBM Hot Topic: Reassessing the Role of Plasma
9310-TC-PBM Hot Topic: Reassessing the Role of Plasma October 24, 2011 10:30 AM - 12:00 PM Event Outline Event Title: 9310-TC-PBM Hot Topic: Reassessing the Role of Plasma Event Date: Monday, October 24,
More informationCofact can be used for: The treatment of haemorrhages or the prevention of peri-operative haemorrhages as the result of
Package leaflet: Information for the user Cofact 250 IU, human prothrombin complex, 250 IU factor IX per vial, powder and solvent for solution for injection. Cofact 500 IU, human prothrombin complex, 500
More informationAnticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT
Haemostasis Thrombosis Phases Endogenous anticoagulants Stopping blood loss Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT Vascular Platelet
More informationNew Age Anticoagulants: Bleeding Considerations
Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University
More informationFrom Lancaster General Health, Lancaster, Pennsylvania
Prothrombin Complex Concentrate Accelerates International Normalized Ratio Reversal and Diminishes the Extension of Intracranial Hemorrhage in Geriatric Trauma Patients MATHEW EDAVETTAL, M.D., PH.D., AMELIA
More informationP-RMS: LT/H/PSUR/0004/001
Core Safety Profile Active substance: Dalteparine Pharmaceutical form(s)/strength: Solution for injection, 2500 I.U./0.2ml, 2500 I.U./ml, 5000 I.U./0.2ml, 7500 I.U./0.3ml, 7500 I.U./0.75ml, 10000 I.U./0.4ml,
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationDOAC and NOAC are terms for a novel class of directly acting oral anticoagulant drugs including Rivaroxaban, Apixaban, Edoxaban, and Dabigatran.
Guideline for Patients on Direct Oral Anticoagulant Therapy Requiring Urgent Surgery for Hip Fracture Trust Ref:C10/2017 1. Introduction This guideline is for the clinical management of patients on direct
More informationStudy design: Multicenter, randomized, controlled, cross-over, blinded PK comparison
Brand Name 1, 2 : Rixubis Generic Name 1, 2 : Coagulation factor IX recombinant Manufacturer 5 : Baxter Drug Class 1, 2, 3 : Antihemophilic agent Labeled Uses 1, 2 : Hemophilia B hemorrhage, routine prophylaxis,
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationBleeding, Coagulopathy, and Thrombosis in the Injured Patient
Bleeding, Coagulopathy, and Thrombosis in the Injured Patient June 7, 2008 Kristan Staudenmayer, MD Trauma Fellow UCSF/SFGH Trauma deaths Sauaia A, et al. J Trauma. Feb 1995;38(2):185 Coagulopathy is Multi-factorial
More information2.5 Other Hematology Consult:
The Warfarin Order Sheet has been approved by the P & T committee to be implemented by pharmacists. These orders are not used to treat patients with serious hemorrhagic complications. WARFARIN TARGET INR
More informationInhixa (Enoxaparin Sodium)
Inhixa (Enoxaparin Sodium) P R E V ENTIS SAFETY D E V I C E P R E V E N T I S I S A N AU TO M AT I C N E E D L E S H I E L D I N G S Y S T E M, W H I C H H A S A C O V E R T H AT E X T E N D S O V E R
More informationApproach to bleeding disorders &treatment. by RAJESH.N General medicine post graduate
Approach to bleeding disorders &treatment by RAJESH.N General medicine post graduate 2 Approach to a patient of bleeding diathesis 1. Clinical evaluation: History, Clinical features 2. Laboratory approach:
More informationNitroglycerin and Heparin Drip Interfacility Protocols
Nitroglycerin and Heparin Drip Interfacility Protocols EMS Protocol This protocol applies to nitroglycerin and Heparin drips that are initiated at the transferring facility prior to transport and are not
More informationPackage leaflet: Information for the user. Prothromplex TOTAL 600 IU
Package leaflet: Information for the user Prothromplex TOTAL 600 IU Powder and solvent for solution for injection Active substance: Human Prothrombin Complex Read all of this leaflet carefully before administration
More informationBlood Thinner Agent. Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy
Blood Thinner Agent Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy Outline: Blood thinner agent definition. anticoagulants drugs. Thrombolytics. Blood thinner agent Therapeutic interference
More informationNew Advances in Transfusion EM I LY CO BERLY, M D
New Advances in Transfusion EM I LY CO BERLY, M D TRANSFUSI ON M EDI CI NE FELLO W VANDERBI LT UNI VERSITY Objectives To discuss the terminology, components, transfusion risks, and dosing guidelines for
More information2. What you need to know before you are given Konakion MM. Package Leaflet: Information for the patient
Package Leaflet: Information for the patient Konakion MM Ampoules 10mg/ml solution for injection Phytomenadione (vitamin K 1 ) Roche Read all of this leaflet carefully before you start taking this medicine
More informationA guide to anticoagulation management and self-testing
A guide to management and self-testing Understanding If you re reading this, you, or someone you care about, may be on oral therapy, usually treated with a vitamin K antagonist (VKA). VKAs, such as warfarin,
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More information10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:
Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division
More informationANTICOAGULANTS AND HIP FRACTURE SURGERY. Jon Antrobus Anaesthetist Borders General Hospital
ANTICOAGULANTS AND HIP FRACTURE SURGERY Jon Antrobus Anaesthetist Borders General Hospital Anticoagulation is common amongst the hip fracture patient population (6-10%) Anticoagulation signifies co-morbidity
More informationUse of Prothrombin Complex Concentrate to Reverse Coagulopathy Rio Grande Trauma Conference
Use of Prothrombin Complex Concentrate to Reverse Coagulopathy Rio Grande Trauma Conference John A. Aucar, MD, MSHI, FACS, CPE EmCare Acute Care Surgery Del Sol Medical Center Associate Professor, University
More informationJohn Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne
John Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne Overview of coagulation Testing coagulation Coagulopathy in ICU Incidence Causes Evaluation Management Coagulation
More information* Sections or subsections omitted from the full prescribing information are not listed.
HIGHLIGHTS OF PRESCRIBIG IFORMATIO These highlights do not include all the information needed to use KCETRA safely and effectively. See full prescribing information for KCETRA. KCETRA (Prothrombin Complex
More informationAnticoagulation. MPharm Programme & OSPAP Programme. Tania Jones Senior Lecturer in Pharmacy Practice & Therapeutics
MPharm Programme & OSPAP Programme Anticoagulation Tania Jones Senior Lecturer in Pharmacy Practice & Therapeutics tania.jones@sunderland.ac.uk Lecture MPHM13 / MPHM14 2017-2018 MPHM13 & MPHM14 Objectives
More informationPrimary Care practice clinics within the Edmonton Southside Primary Care Network.
INR Monitoring and Warfarin Dose Adjustment Last Review: November 2016 Intervention(s) and/or Procedure: Registered Nurses (RNs) adjust warfarin dosage according to individual patient International Normalized
More informationAnticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar
Anticoagulants and Head Injuries Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar Common Anticoagulants and Indications Coumadin (warfarin) indicated for
More informationCitation for published version (APA): Khorsand, N. (2014). Optimal dosing strategy for prothrombin complex concentrate [S.l.]: [S.n.
University of Groningen Optimal dosing strategy for prothrombin complex concentrate Khorsand, Nakisa IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to
More informationFactor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate. From: European Plasma Fractionation Association (EPFA)
Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate Application for retention on the WHO Model List From: European Plasma Fractionation Association (EPFA) 1. Summary
More informationReversal of direct oral anticoagulants in the patient with GI bleeding. Marc Carrier
Reversal of direct oral anticoagulants in the patient with GI bleeding Marc Carrier Disclosure Faculty: Dr. Marc Carrier Relationships with commercial interests: Grants/Research Support: Leo Pharma, Bristol
More informationSUPPORTED BY GUIDELINES Clinical Practice Guidelines Recommend PCC Over Plasma to Reverse the Effects of Warfarin
, Prothrombin Complex Concentrate (Human), is the only FDA-approved alternative to plasma for urgent warfarin reversal SUPPORTED BY GUIDELIES Clinical Practice Guidelines Recommend PCC Over to Reverse
More informationJohn Papadopoulos David R. Schwartz Consulting Editor. Pocket Guide to Critical Care Pharmacotherapy Second Edition
John Papadopoulos David R. Schwartz Consulting Editor Pocket Guide to Critical Care Pharmacotherapy Second Edition 123 Pocket Guide to Critical Care Pharmacotherapy John Papadopoulos Author David R. Schwartz
More informationBleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM
Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients
More informationChapter 1 The Reversing Agents
Available Strategies to Reverse Anticoagulant Medications Michael L. Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Objectives: Describe the pharmacological agents
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationPlatelet-fibrin clot. 50Kd STEMI. Abciximab. Video of a IIb/IIIa inhibitor in action. Unstable Angina and non-stsegment
Objectives IIb/IIIa, Vitamin K, and Direct Thrombin Inhibition in Cardiology Michael Gulseth, Pharm. D., BCPS Assistant Professor, Duluth Pharmacy 6122 February 14, 2005 Describe the pharmacology, kinetics,
More informationKonakion MM. Phytomenadione Composition. Properties and effects. Pharmacokinetics
פורמט עלון זה נקבע ע"י משרד הבריאות ותוכנו נבדק ואושר על ידו בנובמבר 2015 Konakion MM Phytomenadione Composition Active ingredient: phytomenadione (synthetic vitamin K 1 ). Ampoules MM 10 mg/ml in a bile
More informationHaematology Subcommittee of PTAC Meeting held 16 March 2016
Haematology Subcommittee of PTAC Meeting held 16 March 2016 (minutes for web publishing) The Haematology Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationProthromplex TOTAL 600 IU Powder and solvent for solution for injection Active substance: Human Prothrombin Complex
Package leaflet: Information for the user TOTAL 600 IU Powder and solvent for solution for injection Active substance: Prothrombin Complex 0740392 Read all of this leaflet carefully before administration
More informationReversal Agents for NOACs (Novel Oral Anticoagulants)
Reversal Agents for NOACs (Novel Oral Anticoagulants) Current status and future challenges Paul A Reilly, PhD Clinical Research, Boehringer Ingelheim, Inc CSRC Symposium Washington DC Oct 18, 2016 Atrial
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More information6 semanas de embarazo. Critical pt inr levels. Inicio / Embarazo / 6 semanas de embarazo
Inicio / Embarazo / 6 semanas de embarazo 6 semanas de embarazo Critical pt inr levels INR is the result of the patient PT/mean normal PT, exponentially equalized by the ISI. INR levels above 4.9 are considered
More informationDiscussion. Dr Venu 2 nd year, General medicine
Discussion Dr Venu 2 nd year, General medicine Introduction Warfarin-induced skin necrosis (WISN) is usually an unpredictable complication of warfarin therapy, occurring in 0.01-0.1% of warfarin treated
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fibrogammin 250 IU Powder and solvent for solution for injection or infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredient:
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationMANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION IN ADULTS RECEIVING ANTI-COAGULANTS
Hairmyres Hospital MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION IN ADULTS RECEIVING ANTI-COAGULANTS Bleeding in patients on anticoagulants, even in the absence of over-anticoagulation, can be life-threatening
More information